Publication list - Publika - Scientific publications from Oslo University Hospital

Publications by Kushtrim Kryeziu

22 publications found

Original articles

Totland MZ, Knudsen LM, Rasmussen NL, Omori Y, Sørensen V, Elster VCW, Stenersen JM, Larsen M, Jensen CL, Zickfeldt Lade AA, Bruusgaard E, Basing S, Kryeziu K, Brech A, Aasen T, Lothe RA, Leithe E (2024)
The E3 ubiquitin ligase ITCH negatively regulates intercellular communication via gap junctions by targeting connexin43 for lysosomal degradation
Cell Mol Life Sci, 81 (1), 171
DOI 10.1007/s00018-024-05165-8, PubMed 38597989

Caban M, Koblmueller B, Groza D, Schueffl HH, Terenzi A, Tolios A, Mohr T, Mathuber M, Kryeziu K, Jaunecker C, Pirker C, Keppler BK, Berger W, Kowol CR, Heffeter P (2023)
A novel EGFR inhibitor acts as potent tool for hypoxia-activated prodrug systems and exerts strong synergistic activity with VEGFR inhibition in vitro and in vivo
Cancer Lett, 565, 216237
DOI 10.1016/j.canlet.2023.216237, PubMed 37211067

Kryeziu K, Moosavi SH, Bergsland CH, Guren MG, Eide PW, Totland MZ, Lassen K, Abildgaard A, Nesbakken A, Sveen A, Lothe RA (2021)
Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastases
J Transl Med, 19 (1), 384
DOI 10.1186/s12967-021-03062-3, PubMed 34496878

Sveen A, Johannessen B, Eilertsen IA, Røsok BI, Gulla M, Eide PW, Bruun J, Kryeziu K, Meza-Zepeda LA, Myklebost O, Bjørnbeth BA, Skotheim RI, Nesbakken A, Lothe RA (2021)
The expressed mutational landscape of microsatellite stable colorectal cancers
Genome Med, 13 (1), 142
DOI 10.1186/s13073-021-00955-2, PubMed 34470667

Smeby J, Kryeziu K, Berg KCG, Eilertsen IA, Eide PW, Johannessen B, Guren MG, Nesbakken A, Bruun J, Lothe RA, Sveen A (2020)
Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity
EBioMedicine, 59, 102923
DOI 10.1016/j.ebiom.2020.102923, PubMed 32799124

Bruun J, Kryeziu K, Eide PW, Moosavi SH, Eilertsen IA, Langerud J, Røsok B, Totland MZ, Brunsell TH, Pellinen T, Saarela J, Bergsland CH, Palmer HG, Brudvik KW, Guren T, Dienstmann R, Guren MG, Nesbakken A, Bjørnbeth BA, Sveen A, Lothe RA (2020)
Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity
Clin Cancer Res, 26 (15), 4107-4119
DOI 10.1158/1078-0432.CCR-19-3637, PubMed 32299813

Sveen A, Bruun J, Eide PW, Eilertsen IA, Ramirez L, Murumägi A, Arjama M, Danielsen SA, Kryeziu K, Elez E, Tabernero J, Guinney J, Palmer HG, Nesbakken A, Kallioniemi O, Dienstmann R, Lothe RA (2017)
Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies
Clin Cancer Res, 24 (4), 794-806
DOI 10.1158/1078-0432.CCR-17-1234, PubMed 29242316

Schoenhacker-Alte B, Mohr T, Pirker C, Kryeziu K, Kuhn PS, Buck A, Hofmann T, Gerner C, Hermann G, Koellensperger G, Keppler BK, Berger W, Heffeter P (2017)
Sensitivity towards the GRP78 inhibitor KP1339/IT-139 is characterized by apoptosis induction via caspase 8 upon disruption of ER homeostasis
Cancer Lett, 404, 79-88
DOI 10.1016/j.canlet.2017.07.009, PubMed 28716523

Traxl A, Beikbaghban T, Wanek T, Kryeziu K, Pirker C, Mairinger S, Stanek J, Filip T, Sauberer M, Kuntner C, Berger W, Langer O (2017)
[¹¹C]Erlotinib PET cannot detect acquired erlotinib resistance in NSCLC tumor xenografts in mice
Nucl Med Biol, 52, 7-15
DOI 10.1016/j.nucmedbio.2017.05.007, PubMed 28575795

Hoda MA, Pirker C, Dong Y, Schelch K, Heffeter P, Kryeziu K, van Schoonhoven S, Klikovits T, Laszlo V, Rozsas A, Ozsvar J, Klepetko W, Döme B, Grusch M, Hegedüs B, Berger W (2016)
Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro
Mol Cancer Ther, 15 (10), 2357-2369
DOI 10.1158/1535-7163.MCT-15-0846, PubMed 27512118

Henke H, Kryeziu K, Banfić J, Theiner S, Körner W, Brüggemann O, Berger W, Keppler BK, Heffeter P, Teasdale I (2016)
Macromolecular Pt(IV) Prodrugs from Poly(organo)phosphazenes
Macromol Biosci, 16 (8), 1239-1249
DOI 10.1002/mabi.201600035, PubMed 27169668

Kryeziu K, Pirker C, Englinger B, van Schoonhoven S, Spitzwieser M, Mohr T, Körner W, Weinmüllner R, Tav K, Grillari J, Cichna-Markl M, Berger W, Heffeter P (2016)
Chronic arsenic trioxide exposure leads to enhanced aggressiveness via Met oncogene addiction in cancer cells
Oncotarget, 7 (19), 27379-93
DOI 10.18632/oncotarget.8415, PubMed 27036042

Langsteger W, Rezaee A, Loidl W, Geinitz HS, Fitz F, Steinmair M, Broinger G, Pallwien-Prettner L, Beheshti M, Imamovic L, Beheshti M, Rendl G, Hackl D, Tsybrovsky O, Steinmair M, Emmanuel K, Moinfar F, Pirich C, Langsteger W, Bytyqi A, Karanikas G, Mayerhöfer M, Koperek O, Niederle B, Hartenbach M et al. (2016)
32nd International Austrian Winter Symposium : Zell am See, the Netherlands. 20-23 January 2016
EJNMMI Res, 6 (Suppl 1), 32
DOI 10.1186/s13550-016-0168-9, PubMed 27090254

Seršen S, Kljun J, Kryeziu K, Panchuk R, Alte B, Körner W, Heffeter P, Berger W, Turel I (2015)
Structure-Related Mode-of-Action Differences of Anticancer Organoruthenium Complexes with β-Diketonates
J Med Chem, 58 (9), 3984-96
DOI 10.1021/acs.jmedchem.5b00288, PubMed 25856666

Karnthaler-Benbakka C, Groza D, Kryeziu K, Pichler V, Roller A, Berger W, Heffeter P, Kowol CR (2014)
Tumor-targeting of EGFR inhibitors by hypoxia-mediated activation
Angew Chem Int Ed Engl, 53 (47), 12930-12935
DOI 10.1002/anie.201403936, PubMed 25079700

Wilfert S, Iturmendi A, Schoefberger W, Kryeziu K, Heffeter P, Berger W, Brüggemann O, Teasdale I (2014)
Water-Soluble, Biocompatible Polyphosphazenes with Controllable and pH-Promoted Degradation Behavior
J Polym Sci A Polym Chem, 52 (2), 287-294
DOI 10.1002/pola.27002, PubMed 24729657

Fischer B, Heffeter P, Kryeziu K, Gille L, Meier SM, Berger W, Kowol CR, Keppler BK (2013)
Poly(lactic acid) nanoparticles of the lead anticancer ruthenium compound KP1019 and its surfactant-mediated activation
Dalton Trans, 43 (3), 1096-104
DOI 10.1039/c3dt52388h, PubMed 24165902

Heffeter P, Atil B, Kryeziu K, Groza D, Koellensperger G, Körner W, Jungwirth U, Mohr T, Keppler BK, Berger W (2013)
The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo
Eur J Cancer, 49 (15), 3366-75
DOI 10.1016/j.ejca.2013.05.018, PubMed 23790465

Kryeziu K, Jungwirth U, Hoda MA, Ferk F, Knasmüller S, Karnthaler-Benbakka C, Kowol CR, Berger W, Heffeter P (2013)
Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double-strand break repair
Mol Cancer Ther, 12 (6), 1073-84
DOI 10.1158/1535-7163.MCT-13-0065, PubMed 23548265

Review articles

Totland MZ, Omori Y, Sørensen V, Kryeziu K, Aasen T, Brech A, Leithe E (2023)
Endocytic trafficking of connexins in cancer pathogenesis
Biochim Biophys Acta Mol Basis Dis, 1869 (7), 166812
DOI 10.1016/j.bbadis.2023.166812, PubMed 37454772

Kryeziu K, Bruun J, Guren TK, Sveen A, Lothe RA (2019)
Combination therapies with HSP90 inhibitors against colorectal cancer
Biochim Biophys Acta Rev Cancer, 1871 (2), 240-247
DOI 10.1016/j.bbcan.2019.01.002, PubMed 30708039